Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer

Hormones and Cancer

Volumn 1, Issue 1, 2010, Pages 21-33

  Chen, Jie Qing ^a   Litton, Jennifer ^a   Xiao, Li ^a   Zhang, Hua Zhong ^a   Warneke, Carla L ^a   Wu, Yun ^a   Shen, Xiaoyun ^b   Wu, Sheng ^a   Sahin, Aysegul ^a   Katz, Ruth ^a   Bondy, Melissa ^a   Hortobagyi, Gabriel ^a   Berinstein, Neil L ^c   Murray, James L ^a   Radvanyi, Laszlo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Cancer Vaccine Program   (Canada)

Author keywords

Breast cancer; Immunohistochemistry; Trichorhinophalangeal syndrome type 1; Trps 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR GATA; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR TRPS 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DUCT; BREAST HYPERPLASIA; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650217926     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-010-0008-8     Document Type: Article

References (27)

1. Asselin-Labat ML, Sutherland KD, Barker H et al (2007) GATA-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9:201-209
2. Badve S, Nakshatri H (2009) Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 62:6-12
3. Birner P, Oberhuber G, Stani J et al (2001) Evaluation of the United States food and drug administration-approved scoring and test system HER-2 protein expression in breast cancer. Clin Cancer Res 7:1669-1675
4. Black M, Speer F (1982) Nuclear structure in cancer tissue. Surg Gynecol Obstet 105:97-102
5. Chang GTG, Gamble SC, Jhamai M et al (2007) Proteomic analysis of proteins regulated by TRPS-1 transcription factor in CU145 prostate cancer cells. Biochim Biophys Acta 1774:575-582
6. Chang GTG, Jhamai M, van Weerden WM, Jenster G, Brinkmann AO (2004) The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer. Endocr Relat Cancer 11:815-822
7. Chang GTG, van den Bemd GJCM, Jhamai M, Brinkmann AO (2002) Structure and function of GC79/TRPS1, a novel androgen- repressible apoptosis gene. Apoptosis 7:13-21
8. Ciocca V, Daskalakis C, Ciocca RM et al (2009) The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Human Pathol 40:489-495
9. Ciocca V, Daskalakis C, Ciocca RM et al (2009) The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Hum Pathol 40:489-95
10. Fang SH, Chen YZ, Weigel RJ (2008) GATA-3 as a marker of hormone response in breast cancer. J Surg Res 148:1-6
11. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand- binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481
12. Harvey JM et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-81
13. Hoch RV, Thompson DA, Baker RJ et al (1999) GATA-3 is expressed in association with estrogen receptor in breast cancer. Int J Cancer 84:122
14. Kaiser FJ, Brega P, Raff ML et al (2003) Novel missense mutations in the TRPS1 transcription factor define the nuclear localization signal. Eur J Hum Genet 12:121-126
15. Lüdecke HJ, Schaper J, Meinecke P et al (2001) Genotypic and phenotypic spectrum in trichorhinophalangeal syndrome types I and III. Am J Hum Genet 68:81-91
16. Malik TH, von Stechow D, Bronson RT, Shivdasani RA (2002) Deletion of the GATA domain of TRPS1 causes an absence of facial hair and provides new insights into the bone disorder in inherited tricho-rhino-phalangeal syndromes. Mol Cell Biol 22:8592-8600
17. Momeni P, Glöckner G, Schmidt O et al (2000) Mutations in a new gene, encoding a zinc-finger protein, cause tricho-rhinophalangeal syndrome type I. Nat Genet 24:71-74
18. Parikh P, Palazzo JP, Rose LJ et al (2005) GATA-3 expression as a predictor of hormone response in breast cancer. J Am Coll Surg 200:705-10
19. Perdomo J, Crossley M (2002) The Ikaros family protein EOS associates with C-terminal-binding protein corepressors. Eur J Biochem 269:5885-5892
20. Radvanyi L, Singh-Sandhu D, Gallichan S et al (2005) The gene associated with trichorhinophalangeal syndrome in humans is over-expressed in breast cancer. Proc Natl Acad Sci U S A 102:11005-11010
21. Savinainen K, Linja M, Saramäki O et al (2004) Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Can 90:1041-1046
22. Shousha S (2008) Oestrogen receptor status of breast carcinoma: Allred/H score conversion table. Histopathology 53:346-347
23. Tlsty TD (2007) Luminal cells GATA have it. Nat Cell Biol 9:135-136
24. Tong Q, Hotamisligil GS (2007) Developmental biology: cell fate in the mammary gland. Nature 445:724-6
25. van den Bemd G-JCM, Jhamai M, Brinkmann AO, Chang GTG (2003) The atypical GATA protein TRPS1 represses androgen-induced prostate-specific antigen expression in LNCaP prostate cancer cells. Biochem Biophys Res Com 312:578-584
26. WHO (1982) The World Health Organization histological typing of breast tumors-second edition. Am J Clin Pathol 78: 806-816
27. Wolff AC, Hammond MEH, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145